Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis (AMINOPOUCH)
Primary Purpose
Ulcerative Colitis
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Vaminolac
Saline
Sponsored by
About this trial
This is an interventional basic science trial for Ulcerative Colitis
Eligibility Criteria
Inclusion Criteria:
- Patients with ulcerative colitis who are having an ileal pouch-anal anastomosis performed, 18 < age < 50, written informed consent.
Exclusion Criteria:
- Inability to understand written Danish, postmenopause, severe asthma, diabetes mellitus, severe rheumatologic disease, severe comorbidity (ASA group III-IV) in general. Acute or progressing liver failure, uremia without possibility for dialysis, phenylketonuria, defects in amino acid metabolism. Participation in scientific studies in the preceding year, where ionizing radiation has been used, including significant x-ray investigations.
Sites / Locations
- Department of Surgery P, Aarhus University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Vaminolac
Saline
Arm Description
Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
Outcomes
Primary Outcome Measures
Phenylalanine kinetics
Phenylalanine balance is determined by:
PheBal = (PheA - PheV) x F
Where PheBal is the phenylalanine balance (mg/L), PheA is the arterial concentration of phenylalanine, PheV is the venous concentration of phenylalanine, and F is the blood flow.
Tyrosine kinetics
Tyrosine balance is determined by:
TyrBal = (TyrA - TyrV) x F
Where TyrBal is the tyrosine balance, TyrA is the arterial concentration of tyrosine, TyrV is the venous concentration of tyrosine, and F is the blood flow.
Palmitate balance
Palmitate net balance will be estimated using blood flow and arterio-venous differenves in specific activity
Secondary Outcome Measures
Plasma changes in hormones and energy sources
Plasma changes in the levels of insulin, glucagon, catecholamines, cortisol, IGF[1], growth hormone, glycerol, urea, glucose
Full Information
NCT ID
NCT02084550
First Posted
March 5, 2014
Last Updated
July 27, 2017
Sponsor
Aarhus University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02084550
Brief Title
Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis
Acronym
AMINOPOUCH
Official Title
Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 2015 (Actual)
Primary Completion Date
July 1, 2017 (Actual)
Study Completion Date
September 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aarhus University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The detrimental effects of catabolism, insuline resistance and muscle wasting on surgical outcome is wellknown. This catabolism is especially pronounced in patients with acute or chronic inflammation (IBD, cancer) and for those undergoing major surgery. Patients with ulcerative colitis operated with an ileal pouch-anal anastomosis (j-pouch) fall well into both these categories.
To prevent this undesirable catabolism, we will investigate the effects of intravenous administration of predominantly anabolic amino acids (with an amino acid content equal to breast milk) on whole body metabolism, with special emphasis on muscle and fat metabolism and intracellular signalling pathways.
Twenty-four patients will be block-randomized by gender in this parallel-group, randomized, assessor-blinded, placebo-controlled trial to receive either Vaminolac® (Fresenius Kabi) or saline. Metabolism before and after the intervention will be assessed by palmitate- and amino acid kinetics of radioactively labelled tracers, while muscle and fat biopsies will be analyzed for differences in intracellular signaling pathways (PI3 kinase, Akt, etc.) as a measure of cellular activity.
With this study we hope to find evidence for anabolic effects of intravenous amino acids in j-pouch surgery for ulcerative colitis. The perspective is a potential for primary prophylaxis of surgical complications, reduction in the length of hospitalization, and subsequently optimized long-term functional outcome of the pouch.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcerative Colitis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Vaminolac
Arm Type
Active Comparator
Arm Description
Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vaminolac
Intervention Description
Vaminolac with an amino acid content corresponding humane breast milk.
Intervention Type
Other
Intervention Name(s)
Saline
Intervention Description
Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
Primary Outcome Measure Information:
Title
Phenylalanine kinetics
Description
Phenylalanine balance is determined by:
PheBal = (PheA - PheV) x F
Where PheBal is the phenylalanine balance (mg/L), PheA is the arterial concentration of phenylalanine, PheV is the venous concentration of phenylalanine, and F is the blood flow.
Time Frame
6 hours
Title
Tyrosine kinetics
Description
Tyrosine balance is determined by:
TyrBal = (TyrA - TyrV) x F
Where TyrBal is the tyrosine balance, TyrA is the arterial concentration of tyrosine, TyrV is the venous concentration of tyrosine, and F is the blood flow.
Time Frame
6 hours
Title
Palmitate balance
Description
Palmitate net balance will be estimated using blood flow and arterio-venous differenves in specific activity
Time Frame
5 hours
Secondary Outcome Measure Information:
Title
Plasma changes in hormones and energy sources
Description
Plasma changes in the levels of insulin, glucagon, catecholamines, cortisol, IGF[1], growth hormone, glycerol, urea, glucose
Time Frame
6 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with ulcerative colitis who are having an ileal pouch-anal anastomosis performed, 18 < age < 50, written informed consent.
Exclusion Criteria:
Inability to understand written Danish, postmenopause, severe asthma, diabetes mellitus, severe rheumatologic disease, severe comorbidity (ASA group III-IV) in general. Acute or progressing liver failure, uremia without possibility for dialysis, phenylketonuria, defects in amino acid metabolism. Participation in scientific studies in the preceding year, where ionizing radiation has been used, including significant x-ray investigations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Søren Laurberg, MD, DMSc
Organizational Affiliation
Department of Surgery P, Aarhus University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Surgery P, Aarhus University Hospital
City
Aarhus C
ZIP/Postal Code
8000
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis
We'll reach out to this number within 24 hrs